clinical trial · NCT04305548
Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma
Italian Sarcoma Group·phase2·recruiting·n = 16
Mesenchymal ChondrosarcomaTrabectedin
brief summary
Prospective, uncontrolled, investigator-initiated, phase II clinical study to explore the activity of trabectedin in a population of patients aged ≥16 years with progressive, advanced (locally advanced or metastatic)
started
Sep 14, 2021
primary completion
Dec 31, 2026
completion
Dec 31, 2026
last updated
Mar 27, 2026
detailed description
Prospective, uncontrolled, multicenter, Italian, investigator-initiated, phase II clinical study to explore the activity of trabectedin in a population of patients aged ≥16 years with progressive, advanced (locally advanced or metastatic), HEY1-NCOA2 positive MCS) , pre-treated with anthracycline-based chemotherapy.
official title
Phase II Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol